Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6

Cytochrome P450 2D6 (CYP2D6) metabolizes approximately one third of the drugs in current clinical use. To gain insight into its structure and function, we have produced four different sets of comparative models of 2D6: one based on the structures of P450s from four different microorganisms (P450 terp, P450 eryF, P450 cam, and P450 BM3), another on the only mammalian P450 (2C5) structure available, and the other two based on alternative amino acid sequence alignments of 2D6 with all five of these structures. Principal component analysis suggests that inclusion of the 2C5 crystal structure has a profound effect on the modeling process, altering the general topology of the active site, and that the models produced differ significantly from all of the templates. The four models of 2D6 were also used in conjunction with molecular docking to produce complexes with the substrates codeine and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP); this identified Glu 216 [in the F‐helix; substrate recognition site (SRS) 2] as a key determinant in the binding of the basic moiety of the substrate. Our studies suggest that both Asp 301 and Glu 216 are required for metabolism of basic substrates. Furthermore, they suggest that Asp 301 (I‐helix, SRS‐4), a residue thought from mutagenesis studies to bind directly to the basic moiety of substrates, may play a key role in positioning the B′‐C loop (SRS‐1) and that the loss of activity on mutating Asp 301 may therefore be the result of an indirect effect (movement of the B′‐C loop) on replacing this residue. Proteins 2002;49:216–231. © 2002 Wiley‐Liss, Inc.

[1]  C. Chapple,et al.  A cDNA Encoding a Novel Cytochrome P450-Dependent Monooxygenase from Arabidopsis thaliana , 1995, Plant physiology.

[2]  J Berendzen,et al.  The catalytic pathway of cytochrome p450cam at atomic resolution. , 2000, Science.

[3]  P. Ortiz de Montellano,et al.  Active-site topologies of human CYP2D6 and its aspartate-301 --> glutamate, asparagine, and glycine mutants. , 1996, Archives of biochemistry and biophysics.

[4]  Chris Sander,et al.  The FSSP database: fold classification based on structure-structure alignment of proteins , 1996, Nucleic Acids Res..

[5]  F. Gonzalez,et al.  Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s. Transcriptional and post-transcriptional regulation of the rat enzyme. , 1986, The Journal of biological chemistry.

[6]  H. Yamada,et al.  Regiochemistry of cytochrome P450 isozymes. , 1994, Annual review of pharmacology and toxicology.

[7]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[8]  D E McRee,et al.  Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features. , 2000, Journal of inorganic biochemistry.

[9]  W U Primrose,et al.  A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. , 1996, Biochemistry.

[10]  B C Finzel,et al.  Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. , 1986, Biochemistry.

[11]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[12]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[13]  W U Primrose,et al.  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. , 1997, Biochemistry.

[14]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[15]  P. Dayer,et al.  Impact of environmental and genetic factors on codeine analgesia , 2004, European Journal of Clinical Pharmacology.

[16]  M H Tarbit,et al.  Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  T. Poulos,et al.  Structure of cytochrome P450eryF involved in erythromycin biosynthesis , 1995, Nature Structural Biology.

[18]  R. Dixon,et al.  Stress responses in alfalfa (Medicago sativa L.). XVIII: Molecular cloning and expression of the elicitor-inducible cinnamic acid 4-hydroxylase cytochrome P450. , 1993, Archives of biochemistry and biophysics.

[19]  M. Relling.  Polymorphic drug metabolism. , 1989, Clinical pharmacy.

[20]  W L Miller,et al.  Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D S Moss,et al.  Main-chain bond lengths and bond angles in protein structures. , 1993, Journal of molecular biology.

[22]  J. Venhorst,et al.  Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[23]  W. H. Elliott,et al.  The cDNA and protein sequence of a phenobarbital-induced chicken cytochrome P-450. , 1986, The Journal of biological chemistry.

[24]  W. Miller,et al.  Structure of a bovine gene for P-450c21 (steroid 21-hydroxylase) defines a novel cytochrome P-450 gene family. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[26]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[27]  Genetic polymorphisms of drug metabolism * , 1990, Progress in liver diseases.

[28]  M. Kusunose,et al.  Expression and molecular cloning of human liver leukotriene B4 omega-hydroxylase (CYP4F2) gene. , 1999, DNA and cell biology.

[29]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[30]  H. Saedler,et al.  Expression of a cytochrome P450 gene family in maize , 1995, Molecular and General Genetics MGG.

[31]  D. Lewis,et al.  The CYP2 family: models, mutants and interactions. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  J. Mason,et al.  A Novel Cytochrome P450 Expressed Primarily in Brain (*) , 1995, The Journal of Biological Chemistry.

[33]  D. Smith,et al.  Identification of the cytochrome P450 isoforms involved in the O-demethylation of 4-nitroanisole in human liver microsomes. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  N. Vermeulen,et al.  A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.

[35]  Jürgen Brickmann,et al.  A new approach to analysis and display of local lipophilicity/hydrophilicity mapped on molecular surfaces , 1993, J. Comput. Aided Mol. Des..

[36]  H. Yu,et al.  Sequence analysis of ripening-related cytochrome P-450 cDNAs from avocado fruit. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. F. Lewis.  Physical methods in the study of the active site geometry of cytochromes P-450. , 1986, Drug metabolism reviews.

[38]  K. Bozak.  Sequence analysis of ripening-related cytochrom P450 form avacado fruit. , 1990 .

[39]  T. Poulos,et al.  Structure of a cytochrome P450-redox partner electron-transfer complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Eichelbaum,et al.  Influence of the defective metabolism of sparteine on its pharmacokinetics , 1979, European Journal of Clinical Pharmacology.

[41]  D T Jones,et al.  Protein secondary structure prediction based on position-specific scoring matrices. , 1999, Journal of molecular biology.

[42]  Gillian Smith,et al.  Metabolic polymorphisms and cancer susceptibility. , 1995, Cancer surveys.

[43]  M. Schuler,et al.  Cloning of Wound-Induced Cytochrome P450 Monooxygenases Expressed in Pea , 1996, Plant physiology.

[44]  G. Schröder,et al.  Cinnamate 4‐hydroxylase from Catharanthus roseus and a strategy for the functional expression of plant cytochrome P450 proteins as translational fusions with P450 reductase in Escherichia coli , 1995, FEBS letters.

[45]  W. Kalow.  Genetics of drug transformation. , 1986, Clinical biochemistry.

[46]  J. Garnier,et al.  Isolation and sequence of a cDNA encoding the Jerusalem artichoke cinnamate 4-hydroxylase, a major plant cytochrome P450 involved in the general phenylpropanoid pathway. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Cupp-Vickery,et al.  Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. Rane,et al.  Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. , 1991, British journal of clinical pharmacology.

[49]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[50]  J Deisenhofer,et al.  Crystal structure and refinement of cytochrome P450terp at 2.3 A resolution. , 1994, Journal of molecular biology.

[51]  U. Meyer,et al.  Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P‐450IID1 , 1990, Clinical pharmacology and therapy.

[52]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[53]  C. Kozak,et al.  Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. , 1987, DNA.

[54]  B C Finzel,et al.  The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. , 1985, The Journal of biological chemistry.

[55]  G. Cruciani,et al.  Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. , 1994, Journal of medicinal chemistry.

[56]  O. Gotoh,et al.  Structure and drug inducibility of the human cytochrome P-450c gene. , 1986, European journal of biochemistry.

[57]  Y. Ichikawa,et al.  Characterization of the cytochrome P-450IID subfamily in bovine liver. Nucleotide sequences and microheterogeneity. , 1992, European journal of biochemistry.

[58]  A. Lesk,et al.  The relation between the divergence of sequence and structure in proteins. , 1986, The EMBO journal.

[59]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[60]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.

[61]  M J Sternberg,et al.  A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. , 1991, Carcinogenesis.

[62]  U. Meyer,et al.  The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. , 1989, Biochemistry.

[63]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[64]  B. Halkier,et al.  The primary sequence of cytochrome P450tyr, the multifunctional N-hydroxylase catalyzing the conversion of L-tyrosine to p-hydroxyphenylacetaldehyde oxime in the biosynthesis of the cyanogenic glucoside dhurrin in Sorghum bicolor (L.) Moench. , 1995, Archives of biochemistry and biophysics.

[65]  Y. Fujii‐Kuriyama,et al.  A novel species of cytochrome P-450 (P-450ib) specific for the small intestine of rabbits. cDNA cloning and its expression in COS cells. , 1991, The Journal of biological chemistry.

[66]  C Venclovas,et al.  Criteria for evaluating protein structures derived from comparative modeling , 1997, Proteins.

[67]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[68]  F. Guengerich.  Polymorphism of cytochrome P-450 in humans. , 1989, Trends in pharmacological sciences.

[69]  P. Bonnabry,et al.  A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. , 1993, Drugs under experimental and clinical research.

[70]  E. Jabs,et al.  Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. , 1994, The Journal of biological chemistry.

[71]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[72]  C Skoda,et al.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[73]  I. Tanaka,et al.  Crystal structure of nitric oxide reductase from denitrifying fungus Fusarium oxysporum , 1997, Nature Structural Biology.

[74]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[75]  F. Guengerich,et al.  Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. , 1985, Cancer research.

[76]  M. Sutcliffe,et al.  Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity. , 1998, The Biochemical journal.

[77]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[78]  M. S. Kim,et al.  Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. , 2001, Archives of biochemistry and biophysics.

[79]  D. Ohta,et al.  Molecular cloning and sequencing of a cDNA encoding mung bean cytochrome P450 (P450C4H) possessing cinnamate 4-hydroxylase activity. , 1993, Biochemical and biophysical research communications.